What is the best sequence of treatment for patients with EGFR mutations?;Quelle séquence de traitement chez les patients EGFR mutés?

Revue de Pneumologie Clinique

Volumn 67, Issue SUPPL. 1, 2011, Pages

  Besse, B ^a   Zalcman, G ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CHU CÔTE DE NACRE   (France)

Author keywords

Chemotherapy; EGFR mutations; Gefitinib; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; ARTICLE; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIDINES; QUALITY OF LIFE; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79960454385     PISSN: 07618417     EISSN: 17762561     Source Type: Journal    
DOI: 10.1016/S0761-8417(11)70007-4     Document Type: Article

References (32)

1. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
2. Douillard J.Y., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
3. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
4. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
5. Kobayashi K., Inoue A., Maemondo M., Sugawara S., Isobe H., Oizumi S., et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009, 27:15s. [abstr 8016].
6. Janne P.A., Wang X.F., Socinski M.A., Crawford J., Capelletti M., Edelman M.J., et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 2010, 28:15s. [abstr 7503].
7. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
8. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
9. Lee J.S., Park K., Kim S.W., Lee D.H., Kim H.T., Han J.Y., et al. A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the Lung. J Thorac Oncol 2009, 4:S1. [abstr PRS.4].
10. Camidge D.R., Bang Y., Iafrate A.J., Kwak E.L., Maki R.G., Solomon B., et al. Clinival activity of crizotinib (PF-02341066), in ALKpositive patients with non-small cell lung cancer (NSCLC). Ann Oncol 2010, 21. viii122-61. [abstr 366D].
11. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
12. Gandara D.R., Grimminger P.P., Mack P.C., Danenberg P.V., Lara P., Danenberg K.D. Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy. J Clin Oncol 2010, 28:15s. [abstr 7513].
13. Wu J.Y., Shih J.Y., Yang C.H., Chen K.Y., Ho M.L., Yu C.J., et al. Secondline treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer 2010, 126:247-255.
14. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
15. Yang C.H., Fukuoka M., Mok T.S., Wu Y.L., Thongprasert S., Saijo N., et al. Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) V carboplatin/paclitaxel in clinically selected patients with advanced non-small cel lung cancer (NSCLC) in Asia (IPASS). Ann Oncol 2010, 21. viii1-12. [abstr LBA 2].
16. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
17. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
18. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
19. Douillard J.Y., Laporte S., Fossella F., Georgoulias V., Pujol J.L., Kubota K., et al. Comparison of docetaxel- and vinca alkaloidbased chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007, 2:939-946.
20. Kubota K., Watanabe K., Kunitoh H., Noda K., Ichinose Y., Katakami N., et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004, 22:254-261.
21. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
22. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
23. Shepherd F.A., Douillard J., Fukuoka M., Saijo N., Kim S., Cufer T., et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Metaanalysis from four clinical trials. J Clin Oncol 2009, 27:15s. [abstr 8011].
24. Inoue A., Kobayashi K., Usui K., Maemondo M., Okinaga S., Mikami I., et al. First-line gefitinib for patients with advanced non-smallcell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009, 27:1394-1400.
25. Zalcman G., Bergot E. Gefitinib plus docetaxel in non-small-cell lung cancer. Lancet 2009, 373:541.
26. Gridelli C., Ciardiello F., Feld R., Butts C.A., Gebbia V., Genestreti G., et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial. J Clin Oncol 2010, 28:15s. [abstr 7508].
27. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-smallcell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
28. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
29. Janne P.A., Reckamp K., Koczywas M., Camidge D.R., Engelman J.A., Khuri F., et al. A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results. J Thorac Oncol 2009, 4:S1. [abstr A3.1].
30. Heo D.S., Kim J.H., Cho B.C., Ahn M.J., Millham R., Lee S.H., et al. First report of PF 00299804 (PF299) in Asian patients (pts): a Korean phase 1/2 in KRAS wild-type (WT) stage IIIb/IV NSCLC, refractory to chemotherapy and erlotinib or gefitinib. J Thorac Oncol 2009, 4:S1. [abstr A3.2].
31. Yang C.H., Shih J.Y., Su W.C., Hsia T.C., Ho C.L., Dudek A.Z., et al. BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaïve patients with adenocarcinoma of the lung and activating EGFR mutations. J Thorac Oncol 2009, 4:S1. [abstr A3.3].
32. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005, 353:123-132.